Human Pathology
Volume 34, Issue 1 , Pages 41-47 , January 2003

Cell cycle regulators in multiple myeloma: Prognostic implications of p53 nuclear accumulation

,Accepted 26 September 2002.

References 

  1. Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: Increasing evidence for a multistep transformation process. Blood. 1998;91:3–21
  2. El-Deiry WS, Tokino T, Velculescu VE, et al.  WAF1, a potential mediator of p53 tumor suppression. Cell. 1993;75:817–825
  3. Wu X, Bayle JH, Olson D, et al.  The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 1993;7:1126–1132
  4. Portier M, Moles JP, Mazars GR, et al.  p53 and RAS gene mutations in multiple myeloma. Oncogene. 1992;7:2539–2543
  5. Neri A, Baldini L, Trecca D, et al.  p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy. Blood. 1993;81:128–135
  6. Yasuga Y, Hirosawa S, Yamamoto K, et al.  N-ras and p53 gene mutations are very rare events in multiple myeloma. Int J Hematol. 1995;62:91–97
  7. Owen RG, Davis SA, Randerson J, et al.  p53 gene mutations in multiple myeloma. Mol Pathol. 1997;50:18–20
  8. Drach J, Ackermann J, Fritz E, et al.  Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood. 1998;92:802–809
  9. Kawano MM, Mahmoud MS, Ishikawa H. Cyclin D1 and p16INK4A are preferentially expressed in immature and mature myeloma cells, respectively. Brit J Haematol. 1997;99:131–138
  10. Park WH, Seol JG, Kim ES, et al.  Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis. Cancer Res. 2000;60:3065–3071
  11. Teoh G, Urashima M, Ogata A, et al.  MDM2 protein overexpression promotes proliferation and survival of multiple myeloma cells. Blood. 1997;90:1982–1992
  12. Lai R, Medeiros LJ, Wilson CS, et al.  Expression of the cell-cycle–related proteins E2F-1, p53, mdm-2, p21waf-1, and Ki-67 in multiple myeloma: Correlation with cyclin D1 immunoreactivity. Mod Pathol. 1998;11:642–647
  13. Sherr CJ. Cancer cell cycles. Science. 1996;274:1672–1677
  14. Ponce-Castaneda MV, Lee MH, Latres E, et al.  p27kip1: Chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. Cancer Res. 1995;55:1211–1214
  15. Komuro H, Valentine MB, Rubnitz JE, et al.  p27KIP1 deletions in childhood acute lymphoblastic leukemia. Neoplasia. 1999;1:253–261
  16. Donnellan R, Chetty R. Cyclin E in human cancers. FASEB J. 1999;13:773–780
  17. Erlanson M, Portin C, Linderholm B, et al.  Expression of cyclin E and the cyclin-dependent kinase inhibitor p27 in malignant lymphomas: Prognostic implications. Blood. 1998;92:770–777
  18. Yokozawa T, Towatari M, Iida H, et al.  Prognostic significance of the cell cycle inhibitor p27Kip1 in acute myeloid leukemia. Leukemia. 2000;14:28–33
  19. Pruneri G, Fabris S, Baldini L, et al.  Immunohistochemical analysis of cyclin D1 shows deregulated expression in multiple myeloma with the t(11;14). Am J Pathol. 2000;156:1505–1513
  20. Durie BGM, Salmon S. A clinical staging system for multiple myeloma. Cancer. 1975;36:842–854
  21. Bartl R, Frisch B, Fateh-Moghadam A, et al.  Histologic classification and staging of multiple myeloma: A retrospective and prospective study of 674 cases. Am J Clin Pathol. 1987;87:342–355
  22. Attal M, Harousseau JL. Standard therapy versus autologous transplantation in multiple myeloma. Hematol Oncol Clin North Am. 1997;11:133–146
  23. Pruneri G, Pignataro L, Carboni N, et al.  MDM-2 oncoprotein overexpression in laryngeal squamous cell carcinoma: Association with wild-type p53 accumulation. Mod Pathol. 1997;10:785–792
  24. Quintanilla-Martinez L, Thieblemont C, Fend F, et al.  Mantle cell lymphomas lack expression of p27Kip1, a cyclin-dependent kinase inhibitor. Am J Pathol. 1998;153:175–182
  25. Chiarle R, Budel LM, Skolnik J, et al.  Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. Blood. 2000;95:619–626
  26. Soussi T, Beroud C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer. 2001;1:233–240
  27. Michieli P, Chedid M, Lin D, et al.  Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res. 1994;54:3391–3395
  28. Alarcon-Vargas D, Ronai Z. p53-Mdm2—the affair that never ends. Carcinogenesis. 2002;23:541–547
  29. Jones SN, Hancock AR, Vogel H, et al.  Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc Natl Acad Sci U S A. 1998;95:15608–15612
  30. Momand J, Zambetti GP, Olson DC, et al.  The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 1992;69:1237–1245
  31. Oliner JD, Pietenpol J, Thiagalingam S, et al.  Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature. 1993;362:857–860
  32. Momand J, Jung D, Wilczynski S, et al.  The MDM2 gene amplification database. Nucleic Acids Res. 1998;26:3453–3459
  33. Bueso-Ramos CE, Yang Y, deLeon E, et al.  The human MDM-2 oncogene is overexpressed in leukemias. Blood. 1993;82:2617–2623
  34. Preudhomme C, Quesnel B, Vachee A, et al.  Absence of amplification of MDM2 gene, a regulator of p53 function, in myelodysplastic syndromes. Leukemia. 1993;7:1291–1293
  35. Ridge SA, Dyer M, Greaves MF, et al.  Lack of MDM2 amplification in human leukaemia. Brit J Haematol. 1994;86:407–409
  36. Kawamata N, Miller C, Levy V, et al.  mdm-2 oncogene expression in non-Hodgkin's lymphomas. Diagn Mol Pathol. 1996;5:33–38
  37. Capoulade C, Bressac-de Paillerets B, Lefrere I, et al.  Overexpression of MDM2, due to enhanced translation, results in inactivation of wild-type p53 in Burkitt's lymphoma cells. Oncogene. 1998;16:1603–1610
  38. Chen L, Agrawal S, Zhou W, et al.  Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage. Proc Natl Acad Sci U S A. 1998;95:195–200
  39. Capoulade C, Mir LM, Carlier K, et al.  Apoptosis of tumoral and nontumoral lymphoid cells is induced by both mdm2 and p53 antisense oligodeoxynucleotides. Blood. 2001;97:1043–1049
  40. Yamanouchi H, Furihata M, Fujita J, et al.  Expression of cyclin E and cyclin D1 in non-small cell lung cancers. Lung Cancer. 2001;31:3–8
  41. Donnellan R, Kleinschmidt I, Chetty R. Cyclin E immunoexpression in breast ductal carcinoma: Pathologic correlations and prognostic implications. Hum Pathol. 2001;32:89–94
  42. Sgambato A, Cittadini A, Faraglia B, et al.  Multiple functions of p27kip1 and its alterations in tumor cells: A review. J Cell Physiol. 2000;183:18–27
  43. Lotem J, Sachs L. Hematopoietic cells from mice deficient in wild-type p53 are more resistant to induction of apoptosis by some agents. Blood. 1993;82:1092–1096

☆ Address correspondence and reprint requests to Giancarlo Pruneri, MD, Department of Pathology and Laboratory Medicine, European Institute of Oncology, Via Ripamonti 435, Milan, Italy.

PII: S0046-8177(02)29706-3

doi: 10.1053/hupa.2003.6

Human Pathology
Volume 34, Issue 1 , Pages 41-47 , January 2003

Article Tools

* Image Usage & Resolution